Premium
Tie‐1 tyrosine kinase expression in human thyroid neoplasms
Author(s) -
Ito Y,
Yoshida H,
Uruno T,
Nakano K,
Takamura Y,
Miya A,
Kobayashi K,
Yokozawa T,
Matsuzuka F,
Kuma K,
Miyauchi A
Publication year - 2004
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2003.01805.x
Subject(s) - pathology , immunohistochemistry , thyroid , angiogenesis , thyroid carcinoma , receptor tyrosine kinase , adenoma , carcinoma , anaplastic carcinoma , medicine , carcinogenesis , follicular phase , tyrosine kinase , thyroid cancer , cancer research , biology , cancer , receptor
Aims: To investigate tie‐1 expression in human thyroid neoplasms. Recent studies have demonstrated that receptor‐type tyrosine kinases (RTKs) contribute to carcinoma progression. Tie‐1 is one of the RTKs and plays a role in angiogenesis, although its pathophysiological significance in human carcinoma is still to be elucidated. Methods and results: Immunohistochemical expression of tie‐1 was studied in various thyroid neoplasms. Tie‐1 immunoreactivity was only occasionally observed in normal follicular cells. In papillary carcinoma, tie‐1 was classified as positive in carcinoma cells in 55.7% of the cases and was more frequently expressed in those of smaller size with an absence of a poorly differentiated lesion. In contrast, tie‐1 was positive in only 8.3% of anaplastic carcinoma and no cases of follicular carcinoma or adenoma were positive. Conclusions: These results suggest that tie‐1 has a role in thyroid tumorigenesis, especially in the early phase of papillary carcinoma, but it is not important in the progression of anaplastic carcinoma or follicular tumour.